Journal of VitreoRetinal Diseases最新文献

Coring of Intravitreal Medication Vial Stoppers: A Report From the Research in Safety and Therapeutics Committee of the American Society of Retina Specialists. 玻璃体内药物瓶塞的取芯：来自美国视网膜专家学会安全和治疗研究委员会的报告。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-14 DOI: 10.1177/24741264251356296

Ferhina S Ali, Eric W Schneider, Sruthi Arepalli, Durga Borkar, Jordan D Deaner, Nieraj Jain, Nikolas J S London, Ivan J Suner, Akshay S Thomas, Lejla Vajzovic, Robin A Vora, Andre J Witkin

{"title":"Coring of Intravitreal Medication Vial Stoppers: A Report From the Research in Safety and Therapeutics Committee of the American Society of Retina Specialists.","authors":"Ferhina S Ali, Eric W Schneider, Sruthi Arepalli, Durga Borkar, Jordan D Deaner, Nieraj Jain, Nikolas J S London, Ivan J Suner, Akshay S Thomas, Lejla Vajzovic, Robin A Vora, Andre J Witkin","doi":"10.1177/24741264251356296","DOIUrl":"https://doi.org/10.1177/24741264251356296","url":null,"abstract":"In 2024, the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee became aware of reports of coring of vial stoppers in relation to preparation of intravitreal injections. A literature review was performed to further understand and characterize this occurrence within the context of retina practice and the broader medical community. Relevant articles were identified through a systematic search of PubMed using predefined criteria. Coring can be observed when a needle punctures the rubber stopper of a medication vial, pushing a small piece or pieces of the stopper material into the container and introducing extrinsic particles into the drug product. Factors associated with coring include larger gauge needles, perpendicular needle entry, multiple-use vials, and thicker rubber stoppers. Rubber stopper thickness and composition also influence the likelihood of coring. To prevent patient safety issues from coring, filter needles are commonly used to draw up medications from vials because they are effective in mitigating particulate matter from entering syringes. No documented cases of clinical complications related to coring in ophthalmology have been identified. Coring represents an unreported phenomenon in the preparation of intraocular medications. Although there have been no safety implications in retina practice related to coring and intravitreal drug vials, these reports underscore the importance of careful medication preparation, inspection of vials, the use of appropriate needles, and adherence to best clinical practices.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251356296"},"PeriodicalIF":0.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis of Secondary Vitreoretinal Lymphoma With Neurosurgical Stereotactic Biopsy: A Multimodal Diagnostic and Imaging Approach. 继发性玻璃体视网膜淋巴瘤的神经外科立体定向活检诊断：一种多模式诊断和成像方法。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-14 DOI: 10.1177/24741264251356295

Neil Sheth, Margarita De Alba, Nayanika Challa, Michael T Massengill, William F Mieler

{"title":"Diagnosis of Secondary Vitreoretinal Lymphoma With Neurosurgical Stereotactic Biopsy: A Multimodal Diagnostic and Imaging Approach.","authors":"Neil Sheth, Margarita De Alba, Nayanika Challa, Michael T Massengill, William F Mieler","doi":"10.1177/24741264251356295","DOIUrl":"https://doi.org/10.1177/24741264251356295","url":null,"abstract":"Purpose: To describe an atypical diagnostic approach with multimodal imaging analysis in a patient with primary testicular lymphoma who experienced secondary vitreoretinal recurrence. Methods: A single case was evaluated. Results: A complete ophthalmologic examination, including optical coherence tomography (OCT), fluorescein angiography (FA), fundus autofluorescence (FAF), neuroimaging, and stereotactic biopsy, was performed. A dilated fundus examination showed bilateral white subretinal lesions with pinpoint hyperfluorescence on FA and central hypoautofluorescence with peripheral hyperautofluorescence on FAF. OCT revealed bilateral subretinal hyperreflective material. Magnetic resonance imaging of the brain revealed a 7 mm contrast-enhancing lesion of the right thalamus. Following a negative diagnostic vitrectomy, subsequent stereotactic biopsy of the lesion confirmed recurrent lymphoma. Conclusions: This case emphasized the importance of using multidisciplinary methods to confirm a diagnosis of secondary vitreoretinal lymphoma and allowed an appropriate treatment plan to be made.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251356295"},"PeriodicalIF":0.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors for Recurrent Vitreous Hemorrhage After 25-Gauge Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy. 增殖性糖尿病视网膜病变患者玻璃体切除术后玻璃体出血复发的危险因素。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-08 DOI: 10.1177/24741264251351545

Jyotsna Bitra, Haarisudhan Sureshkumar, Abhijith V Eathara, Reem Alahmadi, Michael J Heiferman

{"title":"Risk Factors for Recurrent Vitreous Hemorrhage After 25-Gauge Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.","authors":"Jyotsna Bitra, Haarisudhan Sureshkumar, Abhijith V Eathara, Reem Alahmadi, Michael J Heiferman","doi":"10.1177/24741264251351545","DOIUrl":"10.1177/24741264251351545","url":null,"abstract":"Purpose: To report the incidence of and risk factors associated with recurrent vitreous hemorrhage (VH) in eyes that had 25-gauge pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). Methods: This study included 220 eyes of 185 patients who were 21 years old or older and who had PPV for PDR and a minimum postoperative follow-up of 3 months. For patients who had bilateral PPV, data were gathered from both eyes. If surgery was performed in only 1 eye, data were collected from that eye alone. Results: The incidence of recurrent VH was 34.5% (76 eyes). The VH was categorized as early in 46 eyes (60.5%), delayed in 8 eyes (10.5%), or late in 22 eyes (28.9%). Sixty-eight eyes (89.5%) had mild/moderate recurrent VH and 8 (10.5%) had severe recurrent VH. The mean preoperative fasting blood glucose level was 147.7 mg/dL in eyes without recurrent VH and 176.7 mg/dL in eyes with recurrent VH (P = .020). Younger age (P = .027) and higher diastolic blood pressure at the time of surgery (P = .005) also significantly affected recurrent VH. Conclusions: Younger age, preoperative fasting blood glucose levels, and diastolic blood pressure were significantly associated with recurrent VH after PPV in patients with PDR.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251351545"},"PeriodicalIF":0.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Case of Optic Disc Edema Associated With VEXAS Syndrome. 视盘水肿合并VEXAS综合征一例新病例。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-08 DOI: 10.1177/24741264251351661

Mary A Gao, Tianyu Liu, Sandeep Randhawa

引用次数: 0

Supply Chain Volatility of Repackaged Intravitreal Bevacizumab: A Survey of the American Society of Retina Specialists. 重新包装玻璃体内贝伐单抗的供应链波动：美国视网膜专家协会的一项调查。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-08 DOI: 10.1177/24741264251352889

Hasenin Al-Khersan, Miguel Busquets, Ghassan Ghorayeb, Dan Gong, Anton Kolomeyer, Ella H Leung, Philip Niles, Nimesh A Patel, Ankoor R Shah, Charles C Wykoff, Jill Blim, Michael Jumper, Michael M Lai

{"title":"Supply Chain Volatility of Repackaged Intravitreal Bevacizumab: A Survey of the American Society of Retina Specialists.","authors":"Hasenin Al-Khersan, Miguel Busquets, Ghassan Ghorayeb, Dan Gong, Anton Kolomeyer, Ella H Leung, Philip Niles, Nimesh A Patel, Ankoor R Shah, Charles C Wykoff, Jill Blim, Michael Jumper, Michael M Lai","doi":"10.1177/24741264251352889","DOIUrl":"10.1177/24741264251352889","url":null,"abstract":"Purpose: To characterize retina specialists' perceptions of the intravitreal (IVT) bevacizumab supply chain after the manufacturer, Pine Pharmaceuticals, announced they would no longer produce the formulation. Methods: A 22-question survey was created to assess retina physicians' use of IVT bevacizumab, perceptions of the supply chain, and how the decision will affect patient care. The survey was electronically distributed to all members of the American Society of Retina Specialists. Results: The survey was completed by 287 retina specialists. In the 3 months before the survey, 194 (67.6%) physicians reported receiving IVT bevacizumab from Pine Pharmaceuticals. Approximately 85% of physicians were either very concerned (158 [55.4%]) or concerned (85 [29.8%]) about their access to the medication in the next 3 months. Most physicians anticipated needing to delay or change patient appointments (142 [50.4%]) or change patient treatment plans (179 [63.9%]) because of shortages of IVT bevacizumab. Respondents overwhelmingly believed that patients with step-therapy requirements were most likely to be affected by appointment delays (119 [83.8%]) and changes in treatment plans (140 [78.2%]). Conclusions: The majority of retina specialists surveyed expect the decision to halt production of IVT bevacizumab will significantly disrupt access to the medication and adversely affect patient care. Most physicians predict delays and changes in treatment, particularly for patients with IVT bevacizumab step-therapy requirements. Therefore, to minimize negative effects on patient care, we recommend that carriers suspend step-therapy requirements, especially given that the disruption to the supply chain is likely to be longstanding.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251352889"},"PeriodicalIF":0.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of and Surgical Technique for Treatment With High-Dose Aflibercept. 大剂量阿非利西普治疗的疗效及手术技术。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-08 DOI: 10.1177/24741264251352890

Ahmad M Mansour, Luiz H Lima, Maurizio Battaglia Parodi, Antonio M B Casella, Daniel G Cherfan, J Fernando Arevalo

{"title":"Outcomes of and Surgical Technique for Treatment With High-Dose Aflibercept.","authors":"Ahmad M Mansour, Luiz H Lima, Maurizio Battaglia Parodi, Antonio M B Casella, Daniel G Cherfan, J Fernando Arevalo","doi":"10.1177/24741264251352890","DOIUrl":"10.1177/24741264251352890","url":null,"abstract":"Purpose: To describe an alternate delivery of high-dose aflibercept using previous formulations (ie, prefilled syringe, vial, or compounded). Methods: A prospective pilot study was performed to analyze the short-term safety and visual gain (expressed in logMAR), including increase in intraocular pressure (IOP), resulting from a modified regimen consisting of 0.18 mL paracentesis followed by an intravitreal injection of 0.18 mL aflibercept (prefilled syringe), 0.20 mL aflibercept (vial), or 0.22 mL ziv-aflibercept (compounded). Results: The study comprised 32 eyes (16 naïve; 18 neovascular age-related macular degeneration; 8 retinal vein occlusion). Over a follow-up of 4.1 (± 3.2) months, a mean (± SD) of 1.7 (± 0.9) high-dose injections were administered. The baseline best spectacle-corrected vision was 1.35 ± 0.71 (Snellen VA) and improved to 0.68 ± 0.46 at 1 month (P < .001) and 0.57 ± 0.43 at the final follow-up (P < .001). An increase in IOP of 0.43 ± 4.26 mm Hg was seen 1 minute after injection (P = .58). In 2 eyes (6.3%), reflux as a tiny bleb was noted. Conclusions: When high-dose aflibercept is neither available nor affordable, a patient's readily accessible and cost-effective regimen of aflibercept will allow an exact delivery of high-dose aflibercept, combining minimal drug reflux, minimal immediate increase in IOP, and potential clinical efficacy in the short term.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251352890"},"PeriodicalIF":0.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fulfilling a Sense of Purpose in Medicine. 在医学上实现目标感。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-07 eCollection Date: 2025-07-01 DOI: 10.1177/24741264251352910

Timothy G Murray

引用次数: 0

2025 JVRD Contributor Awards. 2025年JVRD贡献者奖。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-07 eCollection Date: 2025-07-01 DOI: 10.1177/24741264251350192

引用次数: 0

Incidence and Impact of Outer Retinal Folds After Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment Repair. 玻璃体切割修复原发性孔源性视网膜脱离后外视网膜褶皱的发生率及影响。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-06 DOI: 10.1177/24741264251350023

Emily A Eton, Warren W Pan, Cagri G Besirli, David N Zacks, Thomas J Wubben

{"title":"Incidence and Impact of Outer Retinal Folds After Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment Repair.","authors":"Emily A Eton, Warren W Pan, Cagri G Besirli, David N Zacks, Thomas J Wubben","doi":"10.1177/24741264251350023","DOIUrl":"10.1177/24741264251350023","url":null,"abstract":"Purpose: To determine the incidence, risk factors, and visual impact of outer retinal fold formation after pars plana vitrectomy (PPV) for macula-involving rhegmatogenous retinal detachment (RRD).Methods: A retrospective cohort study was performed of patients who had PPV with or without scleral buckling between 2011 and 2021 at a single tertiary referral center. Inclusion criteria were macular optical coherence tomography (OCT) performed within 6 weeks of PPV. Eyes with silicone oil tamponade or redetachment within 12 weeks of repair were excluded. Demographics, ocular characteristics, surgical technique, visual acuity (VA), and OCT data were analyzed.Results: This study included 154 eyes. Outer retinal folds developed in 19.2% of eyes that had OCT within 6 weeks of PPV. The mean time to resolution of an outer retinal fold was 131.9 days. Although eyes with outer retinal folds had worse preoperative vision, there was no difference in the final VA between the groups (preoperative: 20/1099 vs 20/230; P = .003) (12 months postoperative: 20/49 vs 20/46; P = .73). There was a trend toward more superior RRD in patients with outer retinal folds (P = .10).Conclusions: In this study, the incidence of outer retinal folds after PPV for macula-involving RRDs was lower than previously reported. Outer retinal folds that developed soon after surgery resolved quickly, and their presence or absence was not associated with the final VA.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251350023"},"PeriodicalIF":0.5,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of and Risk Factors for Silicone Oil-Associated Cystoid Macular Edema After Pars Plana Vitrectomy. 玻璃体切割术后硅油相关性黄斑囊样水肿的发生率及危险因素分析。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-06-26 DOI: 10.1177/24741264251345845

Jeffrey Liu, William Wirostko, Baseer Ahmad

{"title":"Incidence of and Risk Factors for Silicone Oil-Associated Cystoid Macular Edema After Pars Plana Vitrectomy.","authors":"Jeffrey Liu, William Wirostko, Baseer Ahmad","doi":"10.1177/24741264251345845","DOIUrl":"10.1177/24741264251345845","url":null,"abstract":"Purpose: To observe the incidence of and risk factors for cystoid macular edema (CME) after silicone oil (SO) implantation after pars plana vitrectomy (PPV) for retinal detachment (RD) repair. Methods: This retrospective analysis used the TriNetX database to identify patients who received SO tamponade after PPV for RD between March 2014 and March 2023. The onset and regression of CME were identified using spectral-domain optical coherence tomography. The demographics, intraoperative parameters, and postoperative disease course of patients with and patients without CME were compared using χ2 tests, Student t tests, and logistic regression models. Results: Twenty (25.3%) of 79 eyes developed CME after intraocular insertion of SO. The use of 1000 cs SO (n = 50) vs 5000 cs SO (n = 29) was significantly associated with CME onset (odds ratio, 4.46; P < .05). The mean (± SD) SO tamponade duration was 199.0 ± 125.5 days. The mean time from SO implantation to detection of CME was 82.6 ± 57.9 days. Disease regression occurred in 15 (75.0%) of the 20 eyes with CME and was recorded a mean of 218.2 ± 256.2 days after SO removal. Compared with untreated groups, the frequency of CME regression was not influenced by the administration of sub-Tenon triamcinolone acetonide (75.0% vs 75.0%; P = 1.00), prednisolone acetate eyedrops (75.0% vs 75.0%; P = 1.00), or ketorolac eyedrops (71.4% vs 76.9%; P = .79). Conclusions: The viscosity of the SO used for vitreous tamponade in RD repair may play a role in the development of CME, with lighter grade oil increasing the risk for disease. Furthermore, SO removal alone potentially leads to a prominent reduction in CME in most cases.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251345845"},"PeriodicalIF":0.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0